CD38 and lymphoma: The anti‐CD38 antibodies, Isa, daratumumab, and MOR202 kill CD38+ lymphoma cells via antibody‐dependent cellular cytotoxicity and antibody‐dependent cellular phagocytosis9, 16, 17 In addition, Isa has strong anti‐apoptotic activity in lymphoma cells in the absence of crosslinking agents.17